New Zealand markets close in 3 hours 24 minutes

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
146.07+0.28 (+0.19%)
At close: 04:00PM EDT
146.07 0.00 (0.00%)
After hours: 04:45PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 18.44B
Enterprise value 17.31B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.96
Price/book (mrq)N/A
Enterprise value/revenue 9.47
Enterprise value/EBITDA -80.40

Trading information

Stock price history

Beta (5Y monthly) 0.40
52-week change 3-27.88%
S&P500 52-week change 323.06%
52-week high 3218.88
52-week low 3143.50
50-day moving average 3151.95
200-day moving average 3173.86

Share statistics

Avg vol (3-month) 3851.01k
Avg vol (10-day) 3502.27k
Shares outstanding 5126.45M
Implied shares outstanding 6126.45M
Float 8125.41M
% held by insiders 10.41%
% held by institutions 195.02%
Shares short (28 Mar 2024) 42.8M
Short ratio (28 Mar 2024) 43.86
Short % of float (28 Mar 2024) 42.55%
Short % of shares outstanding (28 Mar 2024) 42.21%
Shares short (prior month 29 Feb 2024) 43.04M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -24.08%
Operating margin (ttm)-26.47%

Management effectiveness

Return on assets (ttm)-4.78%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)1.83B
Revenue per share (ttm)14.64
Quarterly revenue growth (yoy)31.20%
Gross profit (ttm)N/A
EBITDA -228.12M
Net income avi to common (ttm)-440.24M
Diluted EPS (ttm)-3.52
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.44B
Total cash per share (mrq)19.37
Total debt (mrq)2.68B
Total debt/equity (mrq)N/A
Current ratio (mrq)3.08
Book value per share (mrq)-1.75

Cash flow statement

Operating cash flow (ttm)104.16M
Levered free cash flow (ttm)146.53M